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P H Y S I O L O G Y
Systematic evaluation of the association between 
hemoglobin levels and metabolic profile implicates 
beneficial effects of hypoxia
Juha Auvinen1,2†, Joona Tapio3,4†, Ville Karhunen1,5,6†, Johannes Kettunen1,3,7,8,  
Raisa Serpi3,4‡, Elitsa Y. Dimova3,4, Dipender Gill5,9, Pasi Soininen7,8, Tuija Tammelin10, 
Juha Mykkänen11,12, Katri Puukka13, Mika Kähönen14, Emma Raitoharju15, Terho Lehtimäki15, 
Mika Ala-Korpela1,3,7,8, Olli T. Raitakari11,12,16, Sirkka Keinänen-Kiukaanniemi1,17,  
Marjo-Riitta Järvelin1,3,17,18,19*, Peppi Koivunen3,4*
Activation of the hypoxia-inducible factor (HIF) pathway reprograms energy metabolism. Hemoglobin (Hb) is the 
main carrier of oxygen. Using its normal variation as a surrogate measure for hypoxia, we explored whether lower 
Hb levels could lead to healthier metabolic profiles in mice and humans (n = 7175) and used Mendelian random-
ization (MR) to evaluate potential causality (n = 173,480). The results showed evidence for lower Hb levels being 
associated with lower body mass index, better glucose tolerance and other metabolic profiles, lower inflammatory 
load, and blood pressure. Expression of the key HIF target genes SLC2A4 and Slc2a1 in skeletal muscle and adipose 
tissue, respectively, associated with systolic blood pressure in MR analyses and body weight, liver weight, and 
adiposity in mice. Last, manipulation of murine Hb levels mediated changes to key metabolic parameters. In con-
clusion, low-end normal Hb levels may be favorable for metabolic health involving mild chronic activation of the 
HIF response.
INTRODUCTION
Hemoglobin (Hb), an iron-containing metalloprotein in red blood 
cells, is the main carrier of oxygen. Hb levels are regulated geneti-
cally and environmentally, and they vary by sex, ethnicity, age, and 
altitude (1, 2). Individuals’ Hb levels during adult life are, however, 
very stable and used, for example, in the athlete’s biological passport 
to detect blood doping (3). Hb levels directly affect arterial oxygen 
concentration and thereby tissue oxygenation (4, 5). In general, 
high-end Hb levels within the normal range are considered benefi-
cial for health (2). When tissues encounter reduced oxygen levels, 
then as a key transcriptional response, the hypoxia-inducible factor 
(HIF) becomes stabilized. HIF up-regulates genes that induce oxygen 
delivery and reduce its usage, such as those regulating erythropoiesis 
and oxidative energy metabolism, respectively (6). The stability of 
the HIF subunits is governed by three HIF prolyl 4-hydroxylases 
(HIF-P4Hs; also known as PHDs and EGLNs), which require oxy-
gen for catalysis and target HIF for destruction in normoxia (6). 
Three HIF subunits exist, of which HIF1 and HIF2 are the most 
studied (6). Inhibition of HIF-P4Hs and the following activation of 
the HIF response have been shown to protect mice from obesity, 
metabolic dysfunction, and associated diseases (7–10). The evidence 
in human data is largely lacking.
To evaluate whether the HIF response is beneficial for metabolic 
health in humans, we used the normal variation in Hb levels as a 
surrogate measure for oxygenation status. We hypothesized that low-
er Hb levels were hypoxic and could result via HIF-P4H inhibition 
to HIF-mediated reprogramming of energy metabolism and better 
metabolic health (Fig. 1). To test this, we used an innovative and multi-
step systematic and longitudinal approach where we first (i) evaluated 
the association of Hb levels with key metabolic parameters in mice 
and then (ii) examined its associations with more than 170 anthro-
pometric and metabolic parameters in humans in cross-sectional and 
longitudinal settings in two large population-based, sea-level cohorts 
from Finland. Furthermore, we (iii) applied Mendelian randomiza-
tion (MR) analysis to explore potential causality of both Hb levels 
and HIF pathway target gene expression on metabolic traits. In the 
MR paradigm, the use of genetic variants randomly allocated at 
conception to proxy the effect of an exposure can help overcome the 
confounding and reverse causation that hinders causal inference in 
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traditional observational study designs. Last, we (iv) performed a 
venesection intervention study in mice to evaluate the effect of Hb 
level manipulation on body weight, glucose, and lipid metabolism.
RESULTS
Hb levels associate with anthropometric measures in mice 
and humans
First, we evaluated the potential association of Hb levels with key 
metabolic parameters in C57Bl/6 mice and found a positive associ-
ation between Hb levels and body weight at 1 year of age (Fig. 2A). 
Lower Hb levels associated with more favorable glucose tolerance in 
a glucose tolerance test (GTT) and with lower homeostatic model 
assessment of insulin resistance (HOMA-IR) scores (Fig. 2, B and C), 
suggesting that Hb levels may influence metabolic health.
We then examined the association of Hb levels in humans with 
anthropometric and metabolic parameters in a cross-sectional and 
longitudinal design from 31 to 46 years in the general population- 
based, sea-level Northern Finland Birth Cohort 1966 (NFBC1966) 
(11, 12) and searched for a replication in another sea-level cohort, 
Cardiovascular Risk in Young Finns Study (YFS) (13), at a mean age 
of 42 years (table S1 and fig. S1). After adjusting for potential con-
founders, we found a positive association between Hb levels and body 
mass index (BMI) in NFBC1966 at the age of 46 in both sexes (Fig. 3A 
and fig. S2A), and this association was replicated in YFS at 42 years 
[Fig. 3B and table S2, meta-analyzed effect size estimate (Beta) 0.27; 
95% confidence interval (CI) 0.21 to 0.33; P = 2.2 × 10−19]. The in-
crease of 10 g/liter in Hb corresponded to an increase of 3.5% in 
BMI, i.e., in an individual with a BMI of 25.0 kg/m2, this corre-
sponds to a BMI increase of 25.9 kg/m2 (Fig. 3A and table S3). Hb 
levels were also positively associated with waist circumference, hip 
circumference, waist-hip ratio, body fat percentage, and visceral fat 
area, and negatively associated with body muscle mass ratio (Fig. 3B 
and table S2). Thus, the subjects with lower Hb levels appeared to be 
less abdominally obese and to have more muscle tissue. Similar as-
sociations were found for hematocrit levels and red blood cell counts 
with BMI as for Hb in males and females (table S4 and fig. S2, B and 
C). Also, the associations between Hb levels and the anthropometric 
parameters were similar in males and females (fig. S3). We found fur-
ther positive associations between Hb levels and oxygen consumption 
at rest, Hb levels and body fat percentage and oxygen consumption 
at rest, and body fat percentage in a subpopulation of NFBC1966 
(n = 123) (Fig. 3, C to E, and table S5), indicating that the individu-
als with lower Hb levels had less fat and consumed less oxygen.
Lower Hb levels associate with healthier key metabolic 
measures in humans
Hb levels associated with fasting glucose and insulin levels, HOMA-IR 
and HOMA of  cell function (HOMA-) indices, and area under 
the curve (AUC) of glucose and insulin in an oral GTT (OGTT) and 
the Matsuda Index in the meta-analyzed NFBC1966 at 46 years and 
YFS at 42 years, suggesting that subjects with lower Hb levels had 
better glucose tolerance and insulin sensitivity than those with higher 
Hb levels (Fig. 4 and table S6). Hb levels also associated positively 
with systolic blood pressure (SBP) and diastolic blood pressure, se-
rum total cholesterol, low-density lipoprotein cholesterol (LDL-C), 
Fig. 1. Study hypothesis associating lower Hb levels with better metabolic 
health. HIF, hypoxia-inducible factor; HIF-P4H, HIF prolyl 4-hydroxylase; OXPHOS, 
oxidative phosphorylation.
Fig. 2. Association of Hb levels with body weight, glucose tolerance, and insulin resistance in mice. (A) Association of Hb levels with body weight in 1-year-old 
C57Bl/6 male mice (n = 29). (B and C) Association of the highest quartile (High Hb) and the lowest quartile (Low Hb) of Hb levels with GTT area under the curve (AUC) and 
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triglycerides (TG), and serum high-sensitivity (hs) C-reactive protein 
(CRP), respectively, and negatively with high-density lipoprotein cho-
lesterol (HDL-C) levels (Fig. 4 and table S6). The effect sizes of these 
associations weakened when adjusted for BMI, but apart from hsCRP 
and 2-hour glucose, all associations remained below the Bonferroni- 
corrected threshold of P < 0.002 (Fig. 4 and table S6). When com-
paring the associations between males and females, the effect sizes 
were somewhat weaker for females; however, the directions of the 
associations were concordant throughout (fig. S4).
Positive association of Hb levels with metabolic parameters 
strengthens with age
To evaluate the associations of Hb levels with anthropometric and 
metabolic measures in a longitudinal setting, we compared the effect 
sizes of these associations in subjects of NFBC1966 that had been 
examined both at the age of 31 and 46 years (n = 3624). The mean 
Hb levels remained unchanged from 31 to 46 years (fig. S5), and in 
general, the effect sizes of the associations increased with age or re-
mained the same (Fig. 5), the most pronounced increases in effect 
sizes being found for the association of Hb levels with the levels of 
TG, fasting insulin, HOMA-IR, and waist-hip ratio, respectively (Fig. 5 
and tables S7 and S8).
Lower Hb levels associate with less adverse 
metabolite profiles
We then evaluated the associations between Hb levels and systemic 
metabolite profiles of 150 variables analyzed by the nuclear magnetic 
resonance (NMR) metabolomics platform in the meta-analysis of 
Fig. 3. Association of Hb levels with key anthropometric measures and oxygen consumption in human cohorts. (A) Association of Hb levels with BMI in NFBC1966 
at 46 years. Unadjusted regression line (blue) with 95% CIs (gray) of blood Hb levels (g/liter) with BMI (kg/m2). (B) Forest plot representing the effect size estimates and 
their 95% CIs for 1 SD change in anthropometric measures per 1 SD change in Hb. Red, blue, and black lines indicate effect sizes for NFBC1966 at 46 years, YFS at 42 years, 
and meta-analysis, respectively. The effect sizes were adjusted for sex, smoking, physical activity, age, and height for parameters other than BMI. (C to E) Added variable 
plots for sex-adjusted partial associations of Hb levels with oxygen consumption at rest (C), oxygen consumption at rest with body fat percentage (D), and Hb levels with 












Auvinen et al., Sci. Adv. 2021; 7 : eabi4822     14 July 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 12
NFBC1966 at 46 years and YFS at 42 years. Evidence for associations 
of Hb levels was found with lipoprotein subclass particle concentra-
tions and particle sizes and with levels of ApoB, TG and cholesterol 
in lipoproteins, fatty acids (FAs), lactate, glycerol, branched-chain ami-
no acids (isoleucine, leucine, and valine), aromatic amino acids 
(phenylalanine and tyrosine), the inflammatory glycoprotein acetyls, 
creatinine, albumin, and ketone bodies, respectively; these associations 
were mostly positive (Fig. 6 and table S9). We also examined whether 
longitudinal changes in the Hb-metabolite associations are similar 
to the cross-sectional changes. The magnitudes of cross- sectional and 
longitudinal effect estimates of the Hb level difference from 31 to 46 years 
on the NMR metabolite levels in NFBC1966 were consistent (fig. S6). 
The estimated slope for regression of longitudinal effects on cross- 
sectional effects was 0.97 (95% CI 0.89 to 1.05), indicating similar 
effect sizes for both the between-subject and the within-subject effects 
(fig. S6). Higher levels of branched-chain and aromatic amino acids, 
glycoprotein acetyls, and lactate, associated with the higher Hb levels 
here (Fig. 6 and table S9), have previously been associated with insulin 
resistance (14), and the first two have been associated with adiposity 
(15). Moreover, higher phenylalanine levels and higher ratio of 
monounsaturated FAs to all FAs, which associated with higher Hb 
levels here (Fig. 6 and table S9), have earlier been associated with 
increased risk for cardiovascular events (16).
Both Hb levels and expression of HIF target genes associate 
with metabolic traits in causality analyses
We then carried out gene set enrichment analysis (GSEA) by asso-
ciating Hb levels with expression of a set of HIF target genes reported 
to be induced at least fourfold by hypoxia in human peripheral blood 
monocytes (table S10) in whole-blood genome wide-expression data 
in a subpopulation of YFS (n = 1636). After adjustment for con-
founding factors, we found evidence for gene set level transcriptional 
activation of HIF target genes in individuals in the lowest Hb quar-
tile (Hb < 132 g/liter) compared to the highest quartile (Hb > 152 g/
liter) (Fig. 7A).
To evaluate the potential causal effect of Hb levels on the meta-
bolic traits, we conducted MR analyses using genetic association esti-
mates for Hb levels and cardiometabolic outcomes [BMI, HDL-C, 
LDL-C, SBP, type 2 diabetes (T2DM), and TG] from large-scale 
genome-wide association studies (table S11). There was no robust 
evidence for genetically proxied Hb levels being associated with any 
of the considered cardiometabolic traits (figs. S7 and S8). However, 
the point estimates for HDL-C, T2DM, and TG were consistent 
with our hypothesis (Fig. 1 and figs. S7 and S8). We next conducted 
MR using expression quantitative trait loci (eQTL) of HIF target 
genes as the instrumental variables. The results showed genetically 
proxied SLC2A4 expression in skeletal muscle, coding for GLUT4, a 
major glucose transporter, being associated with SBP (Fig. 7B). As a 
Fig. 4. Association of Hb levels with key metabolic parameters. Forest plot rep-
resenting the effect size estimates and their 95% CIs of the association in SD units 
of Hb levels with log(fasting insulin) and fasting glucose levels, log(HOMA-IR) and 
log(HOMA-B) indexes, log(triglycerides), log(AUC of glucose in OGTT)*, log(AUC of 
insulin in OGTT)* and 2-hour glucose in levels in a 2-hour OGTT*, log(Matsuda 
Index)*, fasting serum total cholesterol, HDL cholesterol and LDL cholesterol levels, 
systolic and diastolic blood pressure, and log[high-sensitivity C-reactive protein 
(CRP)] levels in meta-analysis of NFBC1966 at the age of 46 and YFS at 42 years, re-
spectively. * indicates the associations only analyzed in NFBC1966. The effect sizes 
were adjusted for sex, smoking, physical activity (blue), and, in addition, BMI (red). 
Values with ±3 SD exclusions are presented.
Fig. 5. Positive association of Hb levels with most anthropometric and metabolic 
parameters strengthens with age. Effect sizes of association in SD units of Hb 
levels with log(BMI), waist and hip circumference, waist-hip ratio, fasting glucose 
and log(fasting insulin) levels, HOMA-IR and HOMA-B indexes, systolic and diastol-
ic blood pressure, fasting serum cholesterol, LDL cholesterol, HDL cholesterol and 
triglyceride levels, and log(high-sensitivity CRP) in NFBC1966 at the age of 31 (red) 
and 46 (blue) years, respectively. The P values for the difference in effect size be-
tween age 31 and 46 years are indicated. The effect sizes for the anthropometric 
parameters (above the black horizontal line) were adjusted for sex, smoking, phys-
ical activity, and height (excluding BMI), and the metabolic parameters were ad-
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further support, expression of Slc2a1 mRNA, coding for GLUT1, in 
murine white adipose tissue (WAT) associated negatively with 
body weight and the weights of WAT and liver, and similar associ-
ations with glucose level at 2 hours after GTT and Hb were observed 
(Fig. 7C and table S12). Together, these data are consistent with the 
activation of the HIF response being beneficial on the metabolic 
profile.
Manipulation of Hb levels alters metabolism in mice
Last, we returned to the animal experiments and manipulated Hb 
levels in C57Bl/6 mice by venesection, which is followed by a phys-
iological induction of erythropoiesis (17). Our data showed that, in 
2 weeks, the venesection-induced erythropoiesis increased the Hb levels 
in mice and significantly increased body weight and fasting glucose, 
total cholesterol, LDL + VLDL cholesterol and lactate levels, with 
Fig. 6. Higher Hb levels associate with metabolic signatures of adiposity, insulin resistance, and cardiovascular risk. Effect sizes in SD units of association of Hb 
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weaker evidence for an increased HOMA-IR score (P = 0.08) (Fig. 8). 
Association of the change in Hb levels with changes in metabolic pa-
rameters was concordant in effect sizes and consistent across analyses 
(fig. S9) and in agreement with those reported earlier for mice with 
genetically or pharmacologically activated HIF response (9, 18). These 
data show that venesection was associated with systematic change 
in metabolic parameters, potentially due to change in Hb levels.
DISCUSSION
The current study systematically investigated the associations of Hb 
levels with metabolism using observational, experimental, and causal 
analyses approaches. We found a positive association between Hb 
levels and BMI, independently of sex and age. Both males and females 
with the lower Hb levels had better glucose tolerance, lower total 
cholesterol and blood pressure levels, less adverse metabolite pro-
files, and lower inflammatory load. Notably, the observed associa-
tions were not only driven by BMI, and the effect sizes of many of 
them increased with age. Although standard MR analysis did not 
provide robust evidence to support a causal effect of Hb levels on 
cardiometabolic traits, the human eQTL MR and murine adipose 
mRNA expression level analyses indicated association of HIF target 
genes and metabolic regulators, GLUTs 1 and 4, with several key 
metabolic markers. Last, venesection in mice showed evidence for 
causal associations with body weight and metabolic parameters, po-
tentially caused by the manipulation of Hb levels.
A few previous studies with limited sample sizes, selected cohorts, 
cross-sectional setting, and often one sex have shown associations 
Fig. 7. Genetic analyses between Hb levels and HIF target genes and metabolic outcomes. (A) GSEA of the YFS lowest Hb quartile (Hb < 132 g/liter, n = 392) versus 
YFS highest Hb quartile (Hb > 152 g/liter, n = 371) and selected hypoxia-induced HIF target genes. Cohort n = 1636. The analysis was adjusted for sex, age, numbers of 
thrombocytes and leukocytes, the first five principal components of the transcriptomics data, BMI, research center, and three technical microchip variables. (B) eQTL MR 
analyses of selected HIF target genes in the indicated tissues. The hollow point indicates P < 0.00125 (Bonferroni-corrected threshold of 0.05 for 40 exposures). ENO1, 
enolase 1; FLT1, VEGR receptor 1; LOX, lysyl oxidase; P4HA1, collagen prolyl 4-hydroxylase subunit alfa 1; PDK1, pyruvate dehydrogenase kinase 1; PFKL, phosphofructokinase 
liver; PFKM, PFK muscle; PFKP, PFK platelet; SLC2A1, glucose transporter 1; SPP1, secreted phosphoprotein 1; VEGFA, vascular endothelial growth factor A. (C) Association 
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of Hb levels with insulin resistance, hypertension, dyslipidemia, or 
metabolic syndrome (19–23), which are in line with our results. The 
underlying mechanisms have however been poorly understood. Hyper-
viscosity or changes in plasma volume, endothelial cell dysfunction, 
or higher iron/ferritin levels have been suggested as mediators of 
these associations. One study has reported a positive association be-
tween Hb concentration and incidence of metabolic syndrome in men 
(24), and another study has reported an increased risk for T2DM 
with higher hematocrit levels in men (25). The HIF pathway was 
only discovered after these early analyses (6). The current study is 
the first ever that has investigated whether the potential association 
of Hb levels with metabolism would be mediated by tissue oxygen-
ation status involving activation of the HIF response by lower Hb 
levels (Fig. 1). Hb levels can be used as an indicator of tissue oxy-
genation status (4, 5). The results presented here show that Hb lev-
els associated with expression of HIF target genes. One of the key 
metabolic adjustments the hypoxia response confers is transcriptional 
reprogramming of energy metabolism (Fig. 1) (6, 7). HIF target genes 
induce glucose intake insulin independently by up-regulating GLUTs 
and increase glucose usage in glycolysis while dampening the effi-
ciency of the mitochondrial oxidative phosphorylation (6, 7). While 
this mode consumes less oxygen, it also produces less adenosine 
triphosphate and can thus be considered more inefficient. Indi-
viduals being environmentally exposed to hypoxia by living at high 
altitude have been reported to have lower fasting glycemia and bet-
ter glucose tolerance compared to those at near sea level and demo-
graphic studies associate living at high altitude with lower incidence 
of obesity and diabetes (26–28). Furthermore, in clinical trials for 
renal anemia, the first-in-class approved HIF-P4H inhibitor roxa-
dustat, which stabilizes HIF and activates the hypoxia response path-
way, reduced serum cholesterol and TG levels by ≥20% and lowered 
the LDL/HDL ratio (29).
The main strengths of this study are that while the previous studies 
have reported association of Hb levels with a single metabolic or 
cardiovascular health marker, we evaluated association of Hb levels 
with >170 anthropometric, metabolic, and inflammatory parameters 
including systemic metabolite profiles. These previous studies are 
mainly based on small and selected populations, while the current 
study is the largest study carried out in a nonselected birth cohort 
population (n = 5351), including a replication in another Finnish cohort 
(n = 1824; total n = 7175), and it has uniquely both cross-sectional 
and longitudinal design. The results were replicated in another ver-
tebrate species. In addition, no previous studies have used genetic 
instruments for the assessment of these associations or studied met-
abolic effects of Hb manipulation in mice. The limitations of our 
study include the observational nature of human data and that we 
have not measured iron/ferritin levels, which are closely linked to Hb 
levels. However, the mean Hb levels remained stable for the 15-year 
period in the NFBC1966 cohort, suggesting that the low Hb levels 
were not anemic. Moreover, similar associations with BMI were seen 
between hematocrit levels and erythrocyte counts than Hb levels. 
One of the central questions in this study is the causality between 
the Hb levels and the metabolic outcomes. Since HIF is principally 
regulated posttranslationally at the protein level, the use of genetic 
instruments is not feasible and makes the analyses complicated. We 
have therefore used several methods to evaluate the causality of Hb/
oxygen/HIF levels with the metabolic parameters, most of which but 
not all support the lower Hb/oxygen levels to drive the metabolic 
changes. We have used Hb levels in MR as an indirect proxy for 
oxygen in circulation at the population level and carried out look-
ups for relevant traits for eQTLs of HIF target genes. The limitation 
with the eQTL analyses is the concern whether the mRNAs are trans-
lated to proteins proportionally. We have also performed an inter-
vention to manipulate Hb levels and studied its effects on metabolic 
Fig. 8. Manipulation of Hb levels by venesection in mice alters causally metabolic parameters. Hb levels, body weight, fasting blood glucose, fasting serum insulin, 
HOMA-IR, 2-hour blood glucose levels in GTT, total cholesterol, HDL cholesterol, LDL + VLDL cholesterol, triglycerides, and lactate levels of 3-month-old C57Bl/6 male mice 
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parameters. Last, some of the metabolic HIF target genes can also be 
regulated with other transcriptions factors, such as MYC. However, 
this cooperation of MYC with HIF has mainly been reported to oc-
cur in cancer cells with high MYC levels, which is a very different 
setting from a young to middle age population cohort or wild-type 
mice studied here (30).
While more mechanistic studies are needed, our data are consistent 
with lower Hb levels contributing to metabolic and cardiovascular 
health by activating the HIF response that mediates the beneficial 
effects on metabolic health. Thus, the individuals with the lower en-
dogenous Hb levels appear leaner and have a healthier metabolic 
and cardiovascular profile.
MATERIALS AND METHODS
Study design and setting
All animal experiments were carried out with wild-type C57Bl/6N 
mouse cohorts and performed according to protocols approved by 
the Provincial State Office of Southern Finland (license number 
ESAVI/6154/04.10.07/2014). The association of Hb levels with 
anthropometric and metabolic parameters in human was examined 
in cross-sectional and longitudinal design from 31 to 46 years in the 
sea-level general population-based NFBC1966 (11, 12) (n = 3624 at 
31 years and n = 5351 at 46 years), and a replication was performed 
in another sea-level cohort, YFS (13) (n = 1824) at 42 ± 5 years (re-
ferred as 42 years). The flow chart of the study and detailed charac-
teristics of the human study populations are available in table S1 
and fig. S1.
Analyses in mice
Male C57Bl/6N mice (Charles River, Germany) were maintained in 
plastic cages at 21°C with a 12-hour light-dark cycle and free access 
to food. After weaning, the mice were fed Teklad Global 18% Protein 
Rodent Diet (18.6% protein, 6.2% fat, and 44.2% carbohydrates; Envigo); 
from 5 weeks of age, they were fed Teklad Global 19% Protein 
Extruded Rodent Diet (19.0% protein, 9.0% fat, 44.9% carbohydrates; 
Envigo) to slightly support increase in adipocity upon aging. At 
11 months of age, the mice were subjected to a GTT performed after 
12 hours of fasting under fentanyl/fluanisone and midazolam anes-
thesia. Mice were injected intraperitoneally with glucose (1 mg/g), 
and blood glucose concentrations were monitored with a glucometer. 
Serum insulin values were determined with Rat/Mouse Insulin ELISA 
kit (EZRMI-13K; Millipore), and HOMA-IR scores were calculated 
from the glucose and insulin values. The mice were weighed, sam-
pled for Hb (HemoCue Hb 201), and euthanized at the age of 1 year. 
Total RNA was isolated from WAT with an E. Z. N. A. total RNA 
Kit II (Omega Bio-Tek) followed by reverse transcription with an 
iScript cDNA Synthesis Kit (Bio-Rad). Quantitative real-time poly-
merase chain reaction (qPCR) was performed with iTaq SYBR Green 
Supermix with ROX (Bio-Rad) in a C1000 Touch Thermal Cycler 
and a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) 
with primer pairs 5′-AGAACAATCCAGACTAGCAGCA-3′ and 
5′-GGGAACTTCACATCACAGCTC-3′ for Tbp mRNA and Quan-
titect primer assays (Qiagen) for Slc2a1 mRNA.
For the venesection experiment, 3-month-old C57Bl/6N males 
fed Teklad Global 18% Protein Rodent Diet were fasted for 12 hours 
and anesthetized as above. Mice were weighted, and their fasting 
blood glucose and Hb levels and lactate levels were determined with 
a lactometer (Lactate Scout+ -meter, SensLab/EKF Diagnostics). Serum 
samples were collected for determination of fasting insulin and total 
cholesterol, HDL cholesterol, and TG levels by an enzymatic method 
(Roche Diagnostics). The LDL + VLDL levels were calculated from 
the total cholesterol, HDL cholesterol, and TG levels using the Friedewald 
formula (total cholesterol − HDL − (TG/2.2). GTT was performed 
with glucose (2 mg/g), and blood glucose concentration at 2 hours 
was monitored. The mice were then subjected to venesection of 
0.2 ml (~20% blood volume). After 14 days, the same analyses (body 
weight, Hb, fasting glucose, fasting insulin, lactate, GTT, total cho-
lesterol, HDL cholesterol, and TG) were carried out and the mice 
were euthanized.
Human study populations and outcomes
The study conformed to the principles of the Declaration of Helsinki. 
The participants took part on a voluntary basis and signed their in-
formed consent. The data were handled on a group level only, and 
personal information was replaced by identity codes. The research 
protocol was approved by the Ethics Committee of Northern Ostrobothnia 
Hospital District. NFBC1966 participants answered postal question-
naires and went through clinical examinations at 31 and 46 years 
(table S1). Body weight, height, and waist and hip circumference were 
measured at 31 and 46 years, and bioimpedance (body fat mass, 
fat percentage, muscle mass, and visceral fat area) was measured at 
46 years. Fasting blood samples were taken at 31 and 46 years, and 
Hb, serum cholesterol (total, HDL and LDL), TG, glucose, insulin, 
and hsCRP levels and NMR metabolomics (150 metabolites) (31) 
were analyzed. In addition, hematocrit and red blood cell counts 
were analyzed at 46 years, and a 2-hour OGTT was performed at 
46 years with insulin and glucose measurements at baseline and 30, 
60, and 120 min after 75-g glucose intake. To evaluate the insulin 
resist ance and  cell function, HOMA-IR and HOMA- and Matsuda 
indices (32) were calculated based on OGTT insulin and glucose data. 
Brachial systolic and diastolic blood pressure was measured at 31 
and 46 years. At 31 years, resting-state oxygen consumption mea-
surement was performed for an NFBC1966 subpopulation (n = 123) 
at 31 years. NFBC1966 participants reported their smoking habits 
and physical activity at 31 and 46 years, and these were used as con-
founders in the analyses. Individuals using combined oral contra-
ceptives, hormone replacement therapy, or serum lipid–lowering drugs 
were omitted from the metabolomics analyses, as these have been 
shown to greatly influence these measures (table S9).
The YFS participants were examined at the mean age of 42 years 
for body weight, height, and waist and hip circumference, and fast-
ing blood samples were taken for analyses of Hb, serum cholesterol 
(total, HDL and LDL), TG, glucose, insulin and hsCRP levels, and 
NMR metabolomics (150 metabolites). YFS participants also re-
ported their smoking habits and physical activity (13).
Statistical analyses
In the mouse experiments, Student’s t test was used for statistical 
analyses for comparison of the metabolic traits between groups. 
Pearson’s correlation coefficient was calculated to compare linear 
dependences between Slc2a1 mRNA level and each metabolic trait. 
AUC for GTT were calculated by the summary measures method.
In human cohorts, regression models were used to assess the as-
sociations between Hb (main explanatory variable) and anthropo-
metric and metabolic variables (outcome). To adjust for potential 
confounding factors, smoking, physical activity, and sex were in-












Auvinen et al., Sci. Adv. 2021; 7 : eabi4822     14 July 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 12
YFS data, age was also included as a covariate. The analyses were 
conducted including or excluding observations with an absolute 
value more than three SDs off from the mean of Hb or the (poten-
tially transformed) outcome variable. To ease the comparison of 
magnitudes of association across outcomes, the effect size estimates 
are reported in SD units. Of the anthropometric measures, BMI was 
log-transformed (to eliminate skewness and heteroscedasticity in 
model residuals). Height was included as an additional covariate in 
the regression models on anthropometric measures except in the 
model for BMI. Similar regression models were conducted for red 
blood cell counts and hematocrit in addition to Hb, to examine the 
association between these measures and anthropometric variables. 
Of the metabolic parameters, fasting insulin levels, Matsuda and 
HOMA indices, OGTT AUC of glucose and insulin, and TG and 
hsCRP levels were log-transformed to ensure symmetry and ho-
moscedasticity of model residuals. In the hsCRP variable, including 
zeros in the values, the transformation used was log(x + c/2), where 
c = min (xx ≠ 0), i.e., the smallest nonzero value in the variable. Of the 
NMR metabolites, cube root transformation was applied to 144 vari-
ables that were measured in concentrations. The rest were left 
untransformed, except for the degree of unsaturation, which was 
log-transformed to ensure homoscedasticity in model residuals. The 
analyses were first conducted separately for NFBC1966 at 46 years 
and YFS at 42 years and then meta-analyzed for those outcomes 
available in both cohorts using an inverse-variance weighted (IVW) 
random-effects model. The meta-analysis effect sizes were calculat-
ed and reported also in the units in which they were measured. To 
evaluate whether the associations are driven by BMI, all analyses were 
repeated using BMI as an additional explanatory variable. To ac-
count for multiple comparisons, principal components analysis was 
used to estimate the number of independent tests for a Bonferroni- 
style multiple testing correction. As 23 principal components explained 
95% of the variation in the anthropometric and metabolic outcomes, 
a P value of 0.002 (0.05/23) was used as a nominal threshold for sig-
nificance in these analyses. R 3.3.2 software was used for all statistical 
analyses for human samples [R Core Team (2013) www.R-project.org/].
Gene set enrichment analysis
To examine the hypothesized activation of HIF pathway, we performed 
GSEA (33) for a subset of YFS participants at 34 to 49 years (n = 1636) 
with Hb levels and whole-blood genome-wide expression profiling 
data (34). The tested pathway included 22 selected HIF target genes 
as justified in table S10. The analysis was done adjusted for age, sex, 
BMI, YFS study center, leukocyte and thrombocyte counts, five first 
principal components of transcriptomics data, and three technical 
variables from microarray hybridizations (chip, plate, and well). 
The analysis was done with residual gene expression profiles calcu-
lated by linear regression of each gene expression probe and above-
mentioned variables. A nominal P < 0.05 was considered significant.
Mendelian randomization
We conducted MR to investigate the potential causality of Hb levels 
on cardiometabolic traits. In MR, genetic variants, randomly allo-
cated at conception, are used as unconfounded instrumental vari-
ables, proxies, to study the effect of an exposure on an outcome. Genetic 
association estimates for Hb levels were taken from a genome-wide 
association study (GWAS) meta-analysis performed using the 
INTERVAL study, UK Biobank, and UK BiLEVE (a subset of the UK 
Biobank cohort), which included a total of 173,480 subjects of European 
ancestry (35). Adjustments were made for age, sex, BMI, alcohol con-
sumption, and smoking status. For included UK Biobank partici-
pants, the SD of Hb levels was 0.95 g/dl in males and 0.89 mg/dl in 
females. Instruments were selected as variants that associated with 
Hb concentration at genome-wide significance (P < 5 × 10−8) after 
clumping to linkage disequilibrium r2 < 0.001 using the TwoSam-
pleMR package of R (36).
To investigate whether similar results were obtained when using 
Hb genetic association estimates that did not adjust for BMI, alcohol 
consumption, and smoking status, we performed sensitivity analyses 
selecting instruments and genetic association estimates from a GWAS 
on Hb levels in 361,194 UK Biobank participants of European descent, 
with adjustment made for 20 principal components of genetic an-
cestry, age, age2, sex, age × sex, and age2 × sex (Neale Lab accessed 
16 June 2020; rapid GWAS of thousands of phenotypes in the UK 
Biobank 2020 www.nealelab.is/uk-biobank/ukbround2announcement). 
Genetic association estimates for outcomes (BMI, LDL-C, HDL-C, 
TG, SBP, and T2DM) were taken from the published studies detailed 
in table S11 (37–40).
The main MR analysis estimating the association of genetically 
proxied Hb levels with cardiometabolic traits was performed using 
the IVW method (random-effects model) (41). This method com-
bines the causal effect estimates from each individual genetic variant 
(calculated as the ratio of the variant–cardiometabolic trait associa-
tion with the variant–Hb concentration association). It provides a 
reliable estimate if all genetic variants are valid instrumental vari-
ables (42). Sensitivity analyses that relax their assumptions on asso-
ciations of the genetic variants with cardiometabolic traits through 
pathways independent of Hb levels were performed to explore the 
robustness of the findings. Specifically, we performed the weighted 
median method (43) and the Egger method (44). Both of these methods 
provide a statistically consistent estimator of the true causal effect 
under different sets of assumptions. The weighted median provides 
robust causal effect estimates when more than half of the weights of 
genetic variants is provided by valid instruments. The Egger method 
allows all genetic variants to be invalid but requires the pleiotropic 
effects that relate to the cardiometabolic outcomes through pathways 
to be uncorrelated with the genetic variant-Hb associations, and is 
also sensitive to outliers. The intercept test of the Egger method was 
used to test for unbalanced pleiotropy. Causal effect estimates are 
expressed per SD increase in genetically predicted Hb levels.
We also conducted MR to evaluate the effect of expression of 
HIF target genes on the same cardiometabolic traits. The cis-eQTL 
(within ±250 kb of the gene) associations were extracted from the 
GTEx v8 database (45), filtering them by P < 5 × 10−4 and clumping 
them at r2 < 0.1. The same outcome genetic association estimates were 
used as above. The MR effect size was estimated using the Wald 
ratio, and its standard error was calculated using the Delta method. 
All MR analyses were performed with the MendelianRandomization 
package in R (46).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/29/eabi4822/DC1
View/request a protocol for this paper from Bio-protocol.
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